ChemoCentryx, Inc. (CCXI) Q1 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

can, as we've learned more and more about how to work with a brand new high science product like Tavneos in this current environment. The other side is on the patient side. And, you know, again, using hopefully appropriate ways, not hopefully, but definitely using appropriate methods, we'd love to be able to help patients have better, more thorough conversations with their healthcare practitioners about the properties of tabneus, the data, and what it might mean for their particular condition. These are really motivated patients in the ANCA world. They haven't always had much to organize around, frankly, so we're hoping that we can help them, again, with appropriate educational access about not just their disease, but the mechanism of action of this drug, and again, how they might have intelligent conversations with their doctors about what this drug may or may not mean in their particular case. So that's something we're working on very much. And then I guess finally, peer-to-peer discussions, especially in and around major conferences to the extent that, again, we can appropriately encourage those or make those forums available to allow peers to talk to each other about their experience with Dabnios today. I think that's going to be very powerful. because many of those anecdotes are extremely interesting, extremely moving, and I'm hoping we'll start hearing a lot more of that at upcoming meetings like European Renal Association, at ULAR, and then, of course, a little later on at ACR and ASN here in the United States. But access and education, both on the physician and patient side, I think those are big levers. Okay, and what are you hearing about, I guess, from your sales organization in terms of, I guess, the key areas of pushback and the areas that you're having ...